Navigation Links
New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
Date:10/24/2007

which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer in the fourth quarter of 2007, evaluating RDEA119 for inflammatory diseases next year, and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Blurb shows that print still captures imaginations
2. Kauffman study shows consistent entrepreneurial growth
3. Directory shows high-tech growth spurt in Dane Co.
4. Stem cell therapy shows visionary promise
5. TDS restates years of revenues, shows slight profit drop
6. As BIO shows mass of competition, hunt for partners is on
7. UW shows why avian flu hasnt spread among humans yet
8. NameProtect study shows 92% of top brands losing out on search engines
9. Stem cell breakthrough by UW shows why federal research should be broadened
10. Student survey shows surging demand for wireless access
11. Wisconsins tech employment shows increase, HR firm reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... The report expects global cell isolation ... It also provides a carefully analyzed data about the ... the market. , Full Copy of Report @ ... market for cell expansion will keep witnessing growth at ... growth to be driven by rapid technological advancements, government ...
(Date:12/24/2014)... , Dec. 23, 2014 China Biologic ... "Company"), a leading fully integrated plasma-based biopharmaceutical company ... that its majority-owned subsidiary, Shandong Taibang Biological Products ... certification from the China Food and Drug Administration ... facility. As previously disclosed in the Company,s public ...
(Date:12/24/2014)... , December 23, 2014 PharmaBoardroom,s ... , out today and available for free download , ... driving change and growth in the sector today. ... notable successes has been in developing a homegrown pharmaceutical manufacturing ... local production still remains some way off. A cursory comparison ...
(Date:12/24/2014)... 23, 2014  Rock Creek Pharmaceuticals, Inc., (NASDAQ: ... a Clinical Trial Application (CTA) with the ... (MHRA) seeking regulatory approval to initiate clinical trials for ... Contingent on the Company receiving CTA regulatory ... trial to assess the safety, tolerability and dose escalation ...
Breaking Biology Technology:The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... , and VANCOUVER , June 21 ... announced today the initiation of a Phase 3 registration ... being developed for the treatment of castrate-resistant prostate cancer ... SATURN Trial, is the first of three Phase 3 ...
... Employing a Peiner ... of the Utah Science Technology and Research (USTAR) project on the U of U campus. , ... Salt Lake City, Utah (Vocus) June 19, 2010 -- Bigge ... U.S., is assisting in the construction of a new USTAR facility at the University of Utah. ...
... LONDON , June 18, 2010 ... using an artificial pancreas system overnight can,significantly reduce the ... 1 diabetes.(1) Moreover, the first clinical trial of an,artificial ... this system can prevent development of hypoglycemia.(2) The latest ...
Cached Biology Technology:OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer 5Bigge Helps Build New USTAR Complex at the University of Utah 2Artificial Pancreas can Prevent the Development of Hypoglycemia 2Artificial Pancreas can Prevent the Development of Hypoglycemia 3
(Date:12/17/2014)... Dec. 15, 2014 Research and Markets ... of the "Samsung Galaxy S5 - Home ... to their offering. ... different sensing technology than the iPhone 5S, Samsung ... in its product. The Galaxy S5 ...
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... University scientists suggests that a class of material known as ... by the United States Department of Energy (DOE) Hydrogen Program ... hydrogen comes into play as a fuel of the future ... new study by Rice theoretical physicist Boris Yakobson and his ...
... September 30, 2010 (BRONX, NY) The National ... Albert Einstein College of Medicine of Yeshiva University ... and function of thousands of biomedically important proteins. ... toward understanding their role in normal biological processes as ...
... from the biomedical engineering department operated by Georgia Tech ... Director,s New Innovator Award to support a project aimed ... sickle cell disease. Manu Platt, an assistant professor ... will use the National Institutes of Health (NIH) funding ...
Cached Biology News:Hydrogen fuel for thought 2Einstein receives $30 million to study protein form and function 2Einstein receives $30 million to study protein form and function 3Einstein receives $30 million to study protein form and function 4$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 2$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 3$1.5M grant funds research aimed at reducing strokes in children with sickle cell disease 4
Mouse Cell Line Slides...
Request Info...
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
Biology Products: